Tyrosine Kinase/Adaptors
Tyrosine kinase and adaptor inhibitors are compounds that target tyrosine kinases and their associated adaptor proteins, which play pivotal roles in cell signaling, growth, and differentiation. These inhibitors are essential tools in cancer research, as many tyrosine kinases are involved in the signaling pathways that drive tumor growth and metastasis. By inhibiting tyrosine kinases, these compounds can block critical signaling cascades, offering potential therapeutic strategies for various cancers and other diseases involving abnormal cell signaling. At CymitQuimica, we provide a comprehensive range of high-quality tyrosine kinase and adaptor inhibitors to support your research in oncology, molecular biology, and targeted therapy development.
Subcategories of "Tyrosine Kinase/Adaptors"
- ALK(112 products)
- CSF-1R(42 products)
- EGFR(572 products)
- Ephrin Receptor(23 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- HER(5 products)
- Hck(3 products)
- IGF-1R(86 products)
- PDGFR(126 products)
- PYK2(7 products)
- Src(78 products)
- TAM Receptor(32 products)
- Tie-2(20 products)
- Trk receptor(59 products)
- Tyrosine Kinases(27 products)
- VEGFR(268 products)
- c-Fms(108 products)
- c-Kit(101 products)
- c-Met/HGFR(128 products)
- c-RET(51 products)
Show 13 more subcategories
Found 1375 products of "Tyrosine Kinase/Adaptors"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
ROS kinases-IN-1
CAS:<p>ROS kinases-IN-1 is a ROS tyrosine kinase inhibitor with IC50 value of 1.22 μM. ROS kinases-IN-1 shows anti-tumor activity.</p>Formula:C20H16N4OPurity:97.36%Color and Shape:SoildMolecular weight:328.37CH7233163
<p>CH7233163 is a useful organic compound for research related to life sciences and the catalog number is T35334.</p>Purity:98%Color and Shape:SolidUmikibart
<p>Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.</p>Color and Shape:Odour LiquidJBJ-09-063 TFA
<p>JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.</p>Formula:C33H30F4N4O5SColor and Shape:SolidMolecular weight:670.67Dalmitamig
<p>Dalmitamig is a humanized IgG4κ antibody targeting EGFR/CD28, with HumanIgG4(S228P) kappa as its corresponding isotype control.</p>Color and Shape:Odour LiquidSelf-assembling peptide pY1
<p>Self-assembling peptide pY1, which aggregates around cancer cells, specifically targets the EGFR receptor. When co-cultured with Ovalbumin (OVA), pY1 effectively inhibits the endocytosis of OVA.</p>Formula:C104H125N24O29PColor and Shape:SolidMolecular weight:2206.22Taletrectinib free base
CAS:<p>Taletrectinib (AB-106) is a potent, selective oral ROS1/NTRK inhibitor with low IC50s against ROS1 and NTRK1-3, including Crizotinib-resistant mutations.</p>Formula:C23H24FN5OPurity:99.98%Color and Shape:SolidMolecular weight:405.47CRB-0089
<p>CRB-0089 is a human monoclonal antibody targeting NGF/bNGF. It is used in the study of analgesia.</p>Color and Shape:Odour LiquidFicerafusp alfa
<p>Ficerafusp alfa is a chimeric antibody of the IgG1κ type that targets EGFR, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.</p>Color and Shape:Odour LiquidAG-1478 hydrochloride
CAS:<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Formula:C16H15Cl2N3O2Color and Shape:SolidMolecular weight:352.21EGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Formula:C38H47BrFN10O2PColor and Shape:SolidMolecular weight:805.72VEGFR-2-IN-33
<p>VEGFR-2-IN-33 (Compound 4d), a potent VEGFR inhibitor with an IC50 value of 61.04 nM, demonstrates significant inhibition of HepG2 cell proliferation, achieving</p>Formula:C20H14N6O2S2Purity:98%Color and Shape:SolidMolecular weight:434.49c-Met-IN-18
<p>C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.</p>Formula:C21H15FN4O2Purity:98%Color and Shape:SolidMolecular weight:374.37FGFR1 inhibitor-8
<p>FGFR1 inhibitor-8 (Compound 9), an FGFR1 inhibitor with an IC50 of 0.5 nM, binds to the ATP-binding pocket of FGFR1 and exhibits anticancer activity [1].</p>Formula:C26H18ClNO5Purity:98%Color and Shape:SolidMolecular weight:459.88GW297361
CAS:<p>GW297361 is a potent inhibitor of the cell cycle protein-dependent kinase Cdk1 and also inhibits the Pho85 signaling pathway.The IC50s of GW297361 on yeast Cdk1</p>Formula:C16H12N4O3S2Purity:97.02%Color and Shape:SolidMolecular weight:372.42EGFR-IN-42
<p>EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.</p>Formula:C49H53ClFN5O5Color and Shape:SolidMolecular weight:846.43UniPR1449
<p>UniPR1449 is an EphA2 receptor antagonist with a KD of 3.8±2.4 μM, which is significant in cancer pathophysiology [1].</p>Purity:98%Color and Shape:Odour SolidEGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Formula:C27H31N3O2Color and Shape:SolidMolecular weight:429.24163Cofetuzumab
CAS:<p>Cofetuzumab (PF-06523435) is a antibody targeting protein tyrosine kinase 7 (PTK7), which can be used to synthesize ADC compounds like cofetuzumab pelidotin.</p>Purity:>95%Color and Shape:LiquidEGFR-IN-129
<p>EGFR-IN-129 (Compound 10b) is an effective, selective EGFR inhibitor with an IC50 of 51.2 nM and demonstrates broad-spectrum antiproliferative activity against the NCI tumor panel.</p>Formula:C21H18N4O3SColor and Shape:SolidMolecular weight:406.46Nezutatug
CAS:<p>Nezutatug, an anti-HER3 antibody, serves as a research tool in cancer studies [1].</p>Purity:98%Color and Shape:LiquidAZ14240475
<p>AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.</p>Formula:C23H15ClF2N6O2Color and Shape:SolidMolecular weight:480.854ALKBH5-IN-5
CAS:<p>ALKBH5-IN-5 is a highly selective, potent and covalently binding ALKBH5 inhibitor that alters m6A levels on mRNA, induces apoptosis, antitumo.</p>Formula:C13H13NO3Purity:99.54%Color and Shape:SoildMolecular weight:231.25CT52923
CAS:<p>CT52923: selective oral PDGFR blocker, ATP-inhibitor, used in research for various diseases including cancer.</p>Formula:C23H25N5O4SPurity:99.926%Color and Shape:SoildMolecular weight:467.54Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Color and Shape:Odour SolidLMTK3-IN-1
CAS:<p>Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.</p>Formula:C18H11F3N4OPurity:99.89%Color and Shape:SoildMolecular weight:356.3Adimanebart
CAS:<p>Amdokitug is a human-derived IgG1λ monoclonal antibody that acts as an inhibitor of MUSK.</p>Color and Shape:LiquidTyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Color and Shape:Odour SolidFLT3-ITD-IN-2
<p>FLT3-ITD-IN-2 (Compound A1) is an inhibitor of the FLT3-ITD kinase, exhibiting an IC50 of 2.12 nM. It effectively suppresses the proliferation of the FLT3-dependent human AML cell line MOLM-13, with an IC50 of 25.65 nM. FLT3-ITD-IN-2 demonstrates antitumor activity against acute myeloid leukemia.</p>Formula:C39H50N8O6Color and Shape:SolidMolecular weight:726.86U3-1565
<p>U3-1565 (Anti-HB-EGF antibody) is an antibody targeting HB-EGF with potential anti-tumor activity, used in the study of advanced solid tumors.</p>Color and Shape:LiquidMolecular weight:144.82 kDa (Predicted)VEGFR-2-IN-31
<p>VEGFR-2-IN-31 (compound 3i), a robust VEGFR-2 inhibitor (IC50=8.93 nM), serves as an anti-prostate cancer agent by arresting the cell cycle at the S-phase and</p>Formula:C15H10F2N4OPurity:98%Color and Shape:SolidMolecular weight:300.26ALW-II-49-7
CAS:<p>ALW-II-49-7 is a selective and potent inhibitor of EphB2 kinase with an EC50 value of 40 nM in cell.</p>Formula:C21H17F3N4O2Purity:99.72%Color and Shape:SoildMolecular weight:414.38AMG-820
<p>AMG-820 is a human antibody targeting CSF-1R, inhibiting the binding of ligands CSF1 and IL34, and preventing subsequent ligand-induced receptor activation. For AMG-820's isotype control, refer to [Human IgG2 kappa, Isotype Control].</p>Color and Shape:Odour LiquidPyrithyldione
CAS:<p>Pyrithyldione is a sedative-hypnotic agent known to potentially induce agranulocytosis.</p>Formula:C9H13NO2Color and Shape:SolidMolecular weight:167.21EGFR-IN-76
CAS:<p>EGFR-IN-76 is a potent EGFR inhibitor.</p>Formula:C30H30ClFN6O2Purity:97.02% - 97.72%Color and Shape:SolidMolecular weight:561.05VEGFR-2-IN-59
<p>VEGFR-2-IN-59 (Compound 3h) is an inhibitor of VEGFR2 with an IC50 of 3.73 µM. It exhibits cytotoxicity in cancer cell lines A549, HT-29, A375, MCF7, and NHDF, with IC50 values of 20.91, 19.70, 9.63, 17.43, and 20.71 μM, respectively. VEGFR-2-IN-59 also inhibits tubular structure formation and demonstrates anti-angiogenic properties.</p>Formula:C19H20N6O4Color and Shape:SolidMolecular weight:396.4Befotertinib
CAS:<p>Befotertinib (D-0316) is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.</p>Formula:C29H32F3N7O2Purity:99.83%Color and Shape:SolidMolecular weight:567.61JAK1/2/3 Inhibitor 1
CAS:<p>JAK1/2/3 Inhibitor 1 is a potent protein kinase inhibitor.JAK1/2/3 Inhibitor 1 has antitumor activity that inhibits the growth of a variety of cancer cell lines</p>Formula:C6H2Cl2N2SPurity:99.32%Color and Shape:SolidMolecular weight:205.06Varlitinib
CAS:<p>Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.</p>Formula:C22H19ClN6O2SPurity:99.7%Color and Shape:SolidMolecular weight:466.94Valanafusp alfa
CAS:<p>Valanafusp alfa (AGT-181) is a fusion protein targeting HIR and IDUA for MPS I research.</p>Color and Shape:LiquidEGFR-IN-138
<p>EGFR-IN-138 (compound 19) is a potent inhibitor of EGFR, with IC50 values of 37, 2.6, and 1.9 nM for the wild-type, L858R, and T790M EGFR, respectively.</p>Formula:C42H37N7O5Color and Shape:SolidMolecular weight:719.793-Hydroxy Midostaurin
CAS:<p>3-Hydroxy Midostaurin (CGP 52421), a PKC412 metabolite, inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC50 values of roughly 132 nM in</p>Formula:C35H30N4O5Purity:98%Color and Shape:SolidMolecular weight:586.648HER2-IN-14
CAS:<p>HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.</p>Formula:C26H23ClF2N8O3Color and Shape:SolidMolecular weight:568.96HNMPA
CAS:<p>HNMPA blocks insulin receptor kinase, halting autophosphorylation; no impact on cAMP protein kinase or PKC.</p>Formula:C11H11O4PPurity:99.18%Color and Shape:SolidMolecular weight:238.18VGB3
<p>VGB3 is a peptide antagonist of vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2, exhibiting anti-angiogenic and anti-tumor properties. It binds to VEGFR1 and VEGFR2, thereby inhibiting VEGF-driven endothelial cell proliferation, migration, and tube formation, as well as suppressing tumor growth and metastasis in a mouse 4T1 breast cancer model.</p>Formula:C67H101N19O21S2Color and Shape:SolidMolecular weight:1572.76VEGFR2-IN-4
<p>VEGFR2-IN-4 (compound 25) is a potent, selective inhibitor of the VEGFR2 kinase, exhibiting a GI50 of 0.7 nM and demonstrating anti-angiogenic effects.</p>Formula:C23H20N4O3SPurity:98%Color and Shape:SolidMolecular weight:432.49Compound TPX-0046
CAS:<p>Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.</p>Formula:C21H21FN6O3Purity:99.94%Color and Shape:SoildMolecular weight:424.43CREBtide
CAS:<p>CREBtide is a synthetic substrate for PKA (Km=3.9 µM), which is based on the phosphorylation sequence in d-CREB (cAMP response element binding protein).</p>Formula:C73H129N29O19Purity:98%Color and Shape:SolidMolecular weight:1716.99VEGFR-2-IN-32
<p>VEGFR-2-IN-32 (Comp 3a) is an inhibitor of VEGFR-2, exhibiting an inhibitory concentration (IC 50) of 8.93 nM, and demonstrates cytotoxic activity towards PC-3</p>Formula:C15H12N4OPurity:98%Color and Shape:SolidMolecular weight:264.28CSF1R-IN-17
<p>CSF1R-IN-17 (compound 9) is a potent, selective antagonist of CSF1R, exhibiting an inhibition concentration half-maximum (IC50) of 0.2 nM.</p>Formula:C20H25N5O2Purity:98%Color and Shape:SolidMolecular weight:367.44Tyrosine kinase-IN-7
CAS:<p>Tyrosine kinase-IN-7 is a potent inhibitor of the tyrosine kinase EGFR, inhibiting EGFR(WT) and EGFR(T790M) and showing anti-cancer and anti-tumor activity.</p>Formula:C16H15N3OSPurity:99.93%Color and Shape:SolidMolecular weight:297.38BLU-945
CAS:<p>BLU-945 is a reversible, potent, highly selective, and orally available epidermal growth factor receptor tyrosine kinase inhibitor (TKIs).Cost-effective and quality-assured.</p>Formula:C28H37FN6O3SPurity:99.11% - 99.16%Color and Shape:SolidMolecular weight:556.7Varlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Formula:C36H35ClN6O8S3Purity:98%Color and Shape:SolidMolecular weight:811.34Lumretuzumab
CAS:<p>Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity.</p>Purity:95.3% (SDS-PAGE); 96.4% (SEC-HPLC) - 95.3% (SDS-PAGE); 96.4% (SEC-HPLC)Color and Shape:LiquidEGFR/VEGFR2-IN-5
<p>EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.</p>Formula:C17H15N7O5SColor and Shape:SolidMolecular weight:429.41Oritinib
CAS:<p>Oritinib (SH-1028) is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (</p>Formula:C31H37N7O2Purity:99.62%Color and Shape:SoildMolecular weight:539.67PF-04217903 phenolsulfonate
CAS:<p>PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Formula:C25H22N8O5SPurity:98%Color and Shape:SolidMolecular weight:546.56Petosemtamab (FUT8-KO)
<p>Petosemtamab (FUT8-KO) is a variant of Petosemtamab with the fucosyltransferase 8 gene (FUT8) knocked out. Petosemtamab is a monoclonal antibody (mAb) targeting EGFR (with a Kd of 0.22 nM) and LGR5 (with a Kd of 0.86 nM). This antibody disrupts EGFR signaling and causes receptor degradation in LGR5+ cancer cells. It is applicable in research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).</p>Color and Shape:Odour LiquidVEGFR-2-IN-35
<p>VEGFR-2-IN-35 (compound 7) is a potent inhibitor of VEGFR-2, exhibiting an IC50 of 37 nM.</p>Formula:C25H19N3O3Purity:98%Color and Shape:SolidMolecular weight:409.44PROTAC c-Met degrader-1
CAS:<p>PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.</p>Formula:C45H41FN10O5Color and Shape:SolidMolecular weight:820.87Gefitinib N-oxide hydrochloride
<p>Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.</p>Formula:C22H24ClFN4O41·5HClColor and Shape:SolidMolecular weight:517.59TX2-120-1
CAS:<p>TX2-120-1 possesses the ability to bind with Her3, exhibiting an IC50 of 56 nM for Her3. It can be utilized in the synthesis of TX2-121-1.</p>Formula:C26H27N7O2Color and Shape:SolidMolecular weight:469.54Amivantamab (FUT8-KO)
<p>Amivantamab (FUT8-KO) is a humanized dual-specificity antibody targeting EGFR-MET, exhibiting immunotherapeutic anticancer activity. This compound inhibits ligand binding, enhances the internalization and degradation of receptor-antibody complexes, and stimulates macrophage-mediated phagocytosis and natural killer cell cytotoxicity, both of which are Fc-dependent.</p>Formula:C13H12O4Color and Shape:LiquidMolecular weight:232.23Zenocutuzumab
CAS:<p>Zenocutuzumab (MCLA-128) is a humanized antibody targeting HER2, used for research on tumors driven by NRG1 gene rearrangement.</p>Purity:97%Color and Shape:LiquidFRF-06-057
<p>FRF-06-057 is an allosteric ATP EGFR inhibitor targeting both wild-type and mutant EGFR, with IC50 values of 17 nM (LR/TM), 29 nM (LR/TM/CS), 220 nM (LR), and >1000 nM (WT).</p>Formula:C19H13N3O3SColor and Shape:SolidMolecular weight:363.394-Epidoxycycline
CAS:<p>4-Epidoxycycline is a hepatic metabolite of the antibiotic doxycycline and lacks antibiotic properties in mice. In both in vitro assays and in vivo mouse models, 4-Epidoxycycline regulates HER2 gene expression similarly to doxycycline and exhibits comparable efficacy in tumor tissues, achieving over 95% tumor regression rates.</p>Formula:C22H24N2O8Color and Shape:SolidMolecular weight:444.44Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Formula:C41H74N2O20Color and Shape:SolidMolecular weight:915.028SOS1/EGFR-IN-2
<p>SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.</p>Formula:C25H29F3N4O3Color and Shape:SolidMolecular weight:490.52EGFR-IN-128
<p>EGFR-IN-128 (compound 28) is a potent and selective molecule targeting wild-type EGFREx20Ins, demonstrating therapeutic efficacy across various human xenograft models and capable of penetrating the blood-brain barrier in preclinical species.</p>Formula:C27H20N4OColor and Shape:SolidMolecular weight:416.47IMPDH2-IN-4
<p>IMPDH2-IN-4 (compound 2d) is a Mycophenolic acid analog and a selective IMPDH2 inhibitor with a Ki of 1.8 μM. It exhibits potent cytotoxic activity against osteosarcoma cancer cell lines. Additionally, IMPDH2-IN-4 demonstrates high affinity for VEGFR-2, CDK2, and IMPDH.</p>Formula:C35H34O6SiColor and Shape:SolidMolecular weight:578.73Atuzabrutinib
CAS:<p>Atuzabrutinib (SAR 444727) is a selective BTK inhibitor and can be used to study arthritis in rheumatoid rodents and pemphigus vulgaris.</p>Formula:C30H30FN7O2Purity:97.27% - 99.38%Color and Shape:SolidMolecular weight:539.6LCB 03-0110 dihydrochloride
CAS:<p>LCB 03-0110 Dihydrochloride is a potent inhibitor of the c-Src kinase (IC50 = 1.3 nM) and tyrosine kinases in the BTK and SYK family, as well as in the DDR2</p>Formula:C24H25Cl2N3O2SPurity:99.9%Color and Shape:SoildMolecular weight:490.45Tinengotinib
CAS:<p>Tinengotinib is a multikinase inhibitor that targets a series of kinases , including Aurora kinases A/B, JAK1/2, FGFR1/2/3, VEGFRs, and many other kinases.</p>Formula:C20H19ClN6OPurity:99.05%Color and Shape:SolidMolecular weight:394.86JBJ-07-149
CAS:<p>JBJ-07-149 is an inhibitor of EGFRL858R/T790M with an IC50 of 1.1 nM. It suppresses the proliferation of Ba/F3 cells with IC50 values of 4.9 μM when used alone, and 0.148 μM when combined with Cetuximab. Additionally, JBJ-07-149 can serve as a target protein ligand for synthesizing [DDC-01-163].</p>Formula:C28H26N6O2SColor and Shape:SolidMolecular weight:510.61Panomifene HCl
CAS:<p>Panomifene HCl is a selective anti-estrogenic compound with antitumor activity for the treatment of breast cancer.</p>Formula:C25H25ClF3NO2Purity:99.53%Color and Shape:SoildMolecular weight:463.92Anticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Color and Shape:Odour SolidEGFR-IN-136
<p>EGFR-IN-136 (compound 21v) is a potent inhibitor of EGFR, demonstrating IC50 values of 20.2 nM, 1.2 nM, 2.3 nM, and 12.5 nM for EGFRWT, EGFRLR/TM, EGFR19D/TM/CS, and EGFRLR/TM/CS, respectively. It exhibits antiproliferative and antitumor activities and holds potential for research in non-small cell lung cancer (NSCLC).</p>Formula:C30H36N7O4PColor and Shape:SolidMolecular weight:589.625EGFR T790M/L858R-IN-9
<p>EGFRT790M/L858R-IN-9 (Compound 8) is an inhibitor targeting the EGFR-L858R/T790M mutations. It effectively inhibits the phosphorylation of the EGFR-L858R/T790M mutant kinase, demonstrating an IC50 value of 0.0064 µM. Additionally, EGFRT790M/L858R-IN-9 can suppress the proliferation of non-small cell lung cancer (NSCLC) cells, making it useful for cancer research.</p>Formula:C26H27N7O3SColor and Shape:SolidMolecular weight:517.603ARRY-380 (analog )
CAS:<p>ARRY-380 analog (HER2-Inhibitor-1) is a potent and selective HER2 inhibitor.</p>Formula:C29H27N7O4SPurity:99.82%Color and Shape:SolidMolecular weight:569.63EGFR-IN-148
<p>EGFR-IN-148 (compound 8c) is a potent EGFR inhibitor with an IC50 of 0.161 μM. It induces G1/S phase arrest and significantly enhances apoptosis in HepG2 cells.</p>Formula:C17H16N4O4SColor and Shape:SolidMolecular weight:372.398BT-Amide
<p>BT-Amide is an orally active Pyk2 kinase (Pyk2kinase) inhibitor with an IC50 of 44.69 nM. It prevents glucocorticoid-induced bone loss and demonstrates bone-protective activity in C57BL/6 mice.</p>Formula:C29H38ClN7O11P2Color and Shape:SolidMolecular weight:758.053[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)
CAS:<p>Insulin Receptor (1142-1153) binds insulin, is a substrate for its kinase, and has research/medical potential.</p>Formula:C72H110N19O33P3Purity:98%Color and Shape:SolidMolecular weight:1862.67ROS kinases-IN-2
CAS:<p>ROS kinases-IN-2 is a potent ROS kinase inhibitor with an inhibition rate of 21.53% measured at 10 μM.ROS kinases-IN-2 has potential anticancer activity and can</p>Formula:C22H19N3O3S2Purity:99.65% - 99.66%Color and Shape:SolidMolecular weight:437.54SU 4981
CAS:<p>SU 4981 is an inhibitor of VEGFR and a modulator of tyrosine kinase activity.</p>Formula:C19H18N2O2Purity:95.4%Color and Shape:SoildMolecular weight:306.36Herceptide
CAS:<p>Herceptide (HER2-targeting peptide), a peptide that targets HER2, can be conjugated with the near-infrared fluorescent dye indocyanine green (ICG), facilitating the development of theranostic agents.</p>Formula:C76H110N22O23Color and Shape:SolidMolecular weight:1699.82Hck-IN-2
<p>Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.</p>Formula:C36H35FN6O10Color and Shape:SolidMolecular weight:730.696Acrizanib
CAS:<p>Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2.</p>Formula:C20H18F3N7O2Purity:98.71% - 99.64%Color and Shape:SolidMolecular weight:445.4cFMS Receptor Inhibitor IV
CAS:<p>cFMS Receptor Inhibitor IV is an inhibitor of c-Fms tyrosine kinase.</p>Formula:C22H26N4O2Purity:99.70%Color and Shape:SolidMolecular weight:378.47TL13-22
CAS:<p>TL13-22 is a potent inhibitor of ALK and does not lead to degradation of ALK proteins.TL13-22 is often used as a negative control for TL13-12 .</p>Formula:C45H55ClN10O9SPurity:99.13%Color and Shape:SolidMolecular weight:947.5GNQWFI
CAS:<p>GNQWFI, an anti-Flt1 peptide, functions as a VEGFR1-specific antagonist. It inhibits interactions between VEGFR1 and various ligands, such as VEGFA, VEGFB, and placental growth factor (PIGF), and suppresses VEGF-induced endothelial cell migration and tubulogenesis. GNQWFI holds potential for research in cancer, asthma, and other ocular diseases.</p>Formula:C37H49N9O9Color and Shape:SolidMolecular weight:763.84Cinrebafusp alfa
CAS:<p>Cinrebafusp alfa (PRS 343) is an anticalin-based bispecific drug with high affinity for both CD137/HER2, displaying dissociation constants (Kd) of 0.3 nM to</p>Purity:98%Color and Shape:LiquidKemptide Phospho-Ser5
<p>Kemptide (Phospho-Ser5) is a phosphoreceptor peptide that is a specific substrate for camp-dependent protein kinase (PKA).</p>Formula:C32H62N13O12PPurity:98%Color and Shape:SolidMolecular weight:851.89Proinsulin C-peptide (human)
CAS:<p>C-peptide, a 31-amino acid, links Proinsulin A & B chains for correct folding and function.</p>Formula:C129H211N35O48Purity:98%Color and Shape:SolidMolecular weight:3020.26EGFRvIII peptide (PEPvIII)
CAS:<p>PEPvIII, a peptide sequence from EGFRvIII, was designed to represent a target of glioma and is presented by MHC I/II complexes.</p>Formula:C70H111N19O24SPurity:98%Color and Shape:SolidMolecular weight:1634.81Cixutumumab
CAS:<p>Cixutumumab (IMC-A12), a humanized monoclonal antibody targeting IGF-1R, exhibits high affinity and inhibits ligand-dependent receptor activation, impeding</p>Purity:98.5% (SDS-PAGE); 97.5% (SEC-HPLC) - 98.5% (SDS-PAGE); 97.5% (SEC-HPLC)Color and Shape:LiquidErbB-2-binding peptide
CAS:<p>ErbB-2-binding peptide (HER2-binding peptide), a tumor-targeting peptide, holds potential for cancer research applications [1].</p>Formula:C43H60N8O11Color and Shape:SolidMolecular weight:864.98DDR Inhibitor 2
<p>DDR Inhibitor 2 (compound 5a) is a potent inhibitor of the discoidin domain receptor (DDR) with an IC50 value of 0.125 μM, and it is applicable in fibrotic disease research.</p>Formula:C21H23N7OColor and Shape:SolidMolecular weight:389.19641Modotuximab
CAS:<p>Modotuximab (DS 1024) is a humanized antibody targeting EGFR with antitumor activity that accelerates the internalization and degradation of EGFR.</p>Purity:95.5% (SDS-PAGE); 99.3% (SEC-HPLC) - 95.5% (SDS-PAGE); 99.3% (SEC-HPLC)Color and Shape:LiquidGIP (3-42), human acetate
<p>GIP (3-42), human acetate is an antagonist of a glucose-dependent insulinotropic polypeptide (GIP) receptor and regulates insulin secretion and GIP metabolism</p>Purity:98%Color and Shape:LiquidWAY-270360
CAS:<p>WAY-270360 (N-[4-(1H-benzimidazol-2-yl)phenyl]-2,4-dimethoxybenzamide) is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.</p>Formula:C22H19N3O3Purity:98.05%Color and Shape:SolidMolecular weight:373.4KRAS G12D inhibitor 25
CAS:<p>KRAS G12D inhibitor 25 (Compound 148) acts as an inhibitor for KRAS G12C and HSP90α, displaying IC50 values of <0.1 μM and 0.1-1 μM respectively. Additionally, it suppresses the proliferation of MIA PaCa-2 and NCI-H358 cell lines, with EC50 values of <0.1 μM and 0.1-1 μM correspondingly. This compound also promotes the degradation of ERBB2, exhibiting a DC50 of 0.1-1 μM.</p>Formula:C56H62ClN11O6Color and Shape:SolidMolecular weight:1020.62NBI-31772
CAS:<p>NBI-31772 (NBI 31772) is the potent inhibitor of insulin-like growth factor-1 binding protein (IGFBP, Ki = 47 nM).</p>Formula:C17H11NO7Purity:99.79%Color and Shape:SolidMolecular weight:341.27MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
CAS:<p>MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.</p>Formula:C52H72N12O11Purity:97.70%Color and Shape:SolidMolecular weight:1041.2PROTAC EGFR degrader 10
CAS:<p>PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.</p>Formula:C49H65ClN10O7SColor and Shape:SolidMolecular weight:973.62[Pro3]-GIP (Mouse)
<p>GIP receptor blocker, 2.6μM IC50, hinders insulin release, regulates glucose in ob/ob mice, and enhances glucose tolerance.</p>Formula:C225H342N62O64SPurity:98%Color and Shape:SolidMolecular weight:4971.62GW 583340
CAS:<p>GW 583340 is a potent and selective dual inhibitor of EGFR/ErbB2 tyrosine kinase with the advantage of oral dosability and antitumor effects.</p>Formula:C28H25ClFN5O3S2Purity:98.68%Color and Shape:SoildMolecular weight:598.11AVE1642
<p>AVE1642 is a human IgG monoclonal antibody (mAb) that specifically targets CD221/IGF1R. It has the ability to slow the growth of tumor xenografts and extend the survival of tumor-bearing nude mice. AVE1642 is applicable in the study of advanced solid tumors. Recommended isotype control: HumanIgG1kappa, Isotype Control.</p>Color and Shape:Odour LiquidEGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Formula:C26H20ClFN4OSColor and Shape:SolidMolecular weight:490.98Simotinib hydrochloride
CAS:<p>Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.</p>Formula:C25H27Cl2FN4O4Color and Shape:SolidMolecular weight:537.41HER2/neu (654-662) GP2
CAS:<p>Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.</p>Formula:C42H77N9O11Purity:98%Color and Shape:SolidMolecular weight:884.11DP-C-4
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].</p>Color and Shape:LiquidSecretin, canine
CAS:<p>Secretin: endocrine hormone, increases bicarbonate-rich pancreatic fluid, regulates canine gastric functions via Src kinase pathway.</p>Formula:C131H222N44O41Purity:98%Color and Shape:SolidMolecular weight:3069.43EGFR/PI3Kα-IN-1
<p>EGFR/PI3Kα-IN-1 (compound 30k), a dual EGFR/PI3Kα inhibitor, exhibits potent activity with IC 50 values of 3.6 nM (EGFRL858R/T790M) and 30 nM (PI3Kα). It effectively inhibits tumor cell proliferation and demonstrates significant anticancer activity.</p>Formula:C50H49N11O5SColor and Shape:SolidMolecular weight:916.06EGFR-IN-140
<p>EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.</p>Formula:C27H37FN8O2Color and Shape:SolidMolecular weight:524.633PKG inhibitor peptide
CAS:<p>PKG inhibitor; mimics H2B phosphorylation site; Ki=86mM; blocks synthetic substrates, not histone phosphorylation; stops PKA activity on histones.</p>Formula:C38H74N18O10Purity:98%Color and Shape:SolidMolecular weight:943.12cis-NVP-ADW742
CAS:<p>NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.</p>Formula:C28H31N5OColor and Shape:SolidMolecular weight:453.59H1-7 (histone H1 phosphorylation site), PKA Substrate
CAS:<p>H1-7 (histone H1 phosphorylation site), a synthetic polypeptide serving as a PKA substrate, demonstrates utility in PKA substrate applications [1] [2].</p>Formula:C31H58N14O9Color and Shape:SolidMolecular weight:770.88Insulin α-chain (1-13)
CAS:<p>Insulin alpha-chain peptide, amino acids 1-13, T cell-recognized, posttranslationally modified.</p>Formula:C66H118N20O22S3Purity:98%Color and Shape:SolidMolecular weight:1639.96IGF-I (30-41)
CAS:<p>IGF-I (30-41) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).</p>Formula:C51H83N19O19Purity:98%Color and Shape:SolidMolecular weight:1266.34GIP (1-30) amide,human
CAS:<p>GIP (1-30) amide (Human) is a glucose-dependent insulinotropic polypeptide that stimulates insulin secretion, reducing postprandial glycemic issues.</p>Formula:C162H240N40O47SPurity:98%Color and Shape:SolidMolecular weight:3531.94DSPE-PEG1000-GE11
<p>DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.</p>Color and Shape:Odour SolidSTAD 2
CAS:<p>STAD-2 is a cell permeable akap disruptor, selectively binding to pka-rii and blocking the interaction of pka-ri with akap</p>Formula:C102H182N24O22Color and Shape:SolidMolecular weight:2096.724EGFR-IN-110
<p>EGFR-IN-110 (Compound 6) is a covalent inhibitor of EGFR, demonstrating pIC50 values of 9.2 for the EGFR enzyme and 8.7 for EGFR cells. It exhibits strong efficacy in targeting EGFR and maintains good kinase selectivity.</p>Formula:C22H16ClFN4O2Molecular weight:422.09458TrkA-IN-6
<p>TrkA-IN-6 (compound R48) is a hydrazone-based, selective inhibitor of the tropomyosin receptor kinase A (TrkA). It exhibits greater cytotoxicity towards U87 GBM cells compared to Temozolomide, with an IC50 of 68.99 μM.</p>Formula:C16H13N3O5Molecular weight:327.08552PKI(5-24)
CAS:<p>High affinity PKA inhibitor (Ki = 2.3 nM).</p>Formula:C76H129N31O28Purity:98%Color and Shape:SolidMolecular weight:1925.057pYEEI
<p>pYEEI, a tetrapeptide containing phosphotyrosine, binds to the SrcSH2 domain with a dissociation constant (Kd) of 100 nM and an inhibitory concentration (IC50) of 6.5 μM. This compound plays a crucial role in cancer research.</p>Formula:C25H36N3O14PColor and Shape:SolidMolecular weight:633.54PXB17
<p>PXB17 inhibits CSF1R activation (IC50= 1.7 nM) by blocking the PI3K/AKT/mTORC1 signaling pathway. It is effective orally, significantly suppresses the growth of colorectal cancer (CRC), enhances the efficacy of PD-1 monoclonal antibodies (PD-1mAb), and reduces the recurrence of CRC tumors.</p>Formula:C29H35N7O4Molecular weight:545.27505Dacomitinib metabolite M2
CAS:<p>Dacomitinib metabolite M2 is also known as Dacomitinib cysteine conjugate. Dacomitinib inhibits both the wild-type (WT) EGFR and EGFR T790M.</p>Formula:C27H32ClFN6O4SColor and Shape:SolidMolecular weight:591.1Sotuletinib hydrochloride
CAS:<p>Sotuletinib hydrochloride (BLZ945 HCl) is a selective, brain-penetrant CSF-1R (c-Fms) inhibitor (IC50=1 nM),for ALS and TNBC.</p>Formula:C20H23ClN4O3SPurity:98.812%Color and Shape:SolidMolecular weight:434.94Vasonatrin Peptide (VNP)
CAS:<p>Vasonatrin peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) with potent venodilating and natriuretic activity</p>Formula:C123H198N36O36S3Purity:98%Color and Shape:SolidMolecular weight:2865.37MS9427 TFA
<p>MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.</p>Formula:C50H59ClF4N8O14Color and Shape:SolidMolecular weight:1107.5CZY43
<p>CZY43 is an HER3 degrader that effectively induces degradation of HER3 in breast cancer SKBR3 cells in a dose- and time-dependent manner. It efficiently inhibits HER3-dependent signaling and cancer cell growth, outperforming Bosutinib.</p>Formula:C42H53Cl2N5O3Color and Shape:SolidMolecular weight:746.808IGF-I (24-41)
CAS:<p>IGF-I (24-41) is a fragment of IGF-I, affecting GH activities with anabolic, antioxidant, anti-inflammatory, and cytoprotective properties.</p>Formula:C88H133N27O28Purity:98%Color and Shape:SolidMolecular weight:2017.16PRMT5/EGFR-IN-1
<p>PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual inhibitor targeting PRMT5 and EGFR, with IC50 values of 15.47 μM and 19.31 μM, respectively. It demonstrates antiproliferative activity against the A549, MCF7, HeLa, and MDA-MB-231 cell lines. This compound also exhibits favorable pharmacokinetic (PK) and pharmacodynamic (PD) properties in vivo and significantly inhibits the growth of MCF7 orthotopic xenograft tumors.</p>Formula:C27H22F6N2O2Molecular weight:520.15855EGFR/HER2-IN-15
<p>EGFR/HER2-IN-15 is a dihydropyrimidine and an effective inhibitor of EGFR/HER2. It significantly suppresses EGFRwt activity with an IC50 of 37.21 nM and exhibits anticancer properties.</p>Formula:C28H29N3O6Molecular weight:503.20564GIP, human
CAS:<p>Insulinotropic hormone from K-cells, binds GIP receptors, boosts insulin, affects lipids, and has antiapoptotic properties.</p>Formula:C226H338N60O66SPurity:98%Color and Shape:SolidMolecular weight:4983.6c-Kit-IN-6
<p>C-Kit-IN-6 (Compound 101) is an inhibitor of c-Kit, demonstrating IC50 values ranging from 100 nM to 1 μM.</p>Formula:C25H28FN5O5Color and Shape:SolidMolecular weight:497.52Kemptide
CAS:<p>Kemptide is a synthetic heptapeptide, acting as a substrate for cAMP-dependent protein kinase (PK).</p>Formula:C32H61N13O9Purity:98%Color and Shape:SolidMolecular weight:771.91HER2-IN-20
<p>HER2-IN-20 (compound 32) is a potent and selective inhibitor of HER2WT and HER2YVMA, with IC50 values of 49 and 42 nM, respectively. It holds potential for research in non-small cell lung cancer (NSCLC).</p>Formula:C30H27ClFN7O2Molecular weight:571.18988EGFR kinase inhibitor 2
<p>EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting the mutations EGFRL858R/T790M/C797S and EGFRDel19/T790M/C797S. This compound shows potential in addressing acquired resistance in the treatment of non-small cell lung cancer.</p>Formula:C39H40N6O5Molecular weight:672.30602ZM 449829
CAS:<p>ZM 449829: Selective JAK3 inhibitor, binds to ATP site. pIC50: 6.8 for JAK3, others < 5.0.</p>Formula:C13H10OPurity:98%Color and Shape:SolidMolecular weight:182.222EGFR-IN-93
<p>EGFR-IN-93 (compound 18) is an allosteric inhibitor of the T790M/L858R double mutant EGFR. It is applicable for research in non-small cell lung cancer (NSCLC).</p>Formula:C22H18FN3O3Molecular weight:391.13322Enapotamab vedotin
CAS:<p>Enapotamab vedotin (anti-AXL ADC) targets AXL with MMAE payload, showing potential against AXL-expressing, EGFR-resistant NSCLC.</p>Purity:95%Color and Shape:LiquidTimigutuzumab
CAS:<p>Timigutuzumab (GEXMab73) is a humanized monoclonal antibody designed to target ErbB2, showing potential application in cancer research [1].</p>Color and Shape:LiquidHDS 029
CAS:<p>HDS 029 has a wide range of applications in life science related research.</p>Formula:C17H11ClFN5OColor and Shape:SolidMolecular weight:355.76Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH
CAS:<p>Phosphopeptide ligand for the src SH2 domain (IC50 = 1 μM). Blocks src interactions with EGFR and FAK.</p>Formula:C32H46N5O17PPurity:98%Color and Shape:SolidMolecular weight:803.71HER2/neu (654-662) GP2 acetate
<p>GP2 acetate, from HER2 (654-662), triggers HLA-A2-restricted T cells to attack epithelial cancers.</p>Formula:C44H81N9O13Purity:98%Color and Shape:SolidMolecular weight:944.17Gastric Inhibitory Peptide (1-42) (porcine) TFA
<p>Gastric Inhibitory Peptide (1-42) (porcine) TFA is a glucose-dependent insulinotropic polypeptide released by intestinal K-cells.</p>Formula:C225H342N60O66S·XCF3COOHColor and Shape:SolidMolecular weight:4975.55EGFR-IN-95
<p>EGFR-IN-95 is a derivative of 2,4-diaminonicotinamide. It effectively inhibits the activity of EGFRdel19/T790M/C797S and L858R/T790M/C797S.</p>Formula:C23H28F2N8O3SMolecular weight:534.19731BI-4732
CAS:<p>DL-Homocystine is a mutagen secreted by F. nucleatum.</p>Formula:C32H36N10O2Purity:98.88%Color and Shape:SolidMolecular weight:592.69EGFR WT/T790M/L858R-IN-1
<p>EGFRWT/T790M/L858R-IN-1 (compound 10d) is a potent inhibitor of EGFR, demonstrating IC50 values of 0.097, 0.280, and 0.051 μM for EGFRWT, EGFRT790M, and EGFRL858R, respectively. This compound can be utilized in cancer research.</p>Formula:C26H25Cl3N2O3Molecular weight:518.09308evobrutinib
CAS:<p>Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the</p>Formula:C25H27N5O2Purity:98.03% - 99.58%Color and Shape:SolidMolecular weight:429.51Anti-TrkB/NTRK2 Antibody
<p>Anti-TrkB/NTRK2 Antibody is a human-derived antibody produced in CHO cells, targeting TrkB. For the isotype control of Anti-TrkB/NTRK2 Antibody, refer to HumanIgG2kappa, Isotype Control.</p>Color and Shape:Odour LiquidMS39N
CAS:<p>MS39N (compound 27) serves as the negative control for MS39, capable of binding to EGFR without causing its degradation.</p>Formula:C55H71ClFN9O7SMolecular weight:1056.73CN009543V
CAS:<p>CN009543V is an enhancer of tyrosine phosphorylation of EGFR via downstream signaling pathways.</p>Formula:C12H12N4O6SColor and Shape:SolidMolecular weight:340.31IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Color and Shape:Odour LiquidGNF2133
CAS:<p>GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.</p>Formula:C24H30N6O2Purity:98.51%Color and Shape:SolidMolecular weight:434.53Inetetamab
<p>Inetetamab is a recombinant humanized antibody targeting HER2 receptor domain IV, with anticancer activity, inducing pyroptosis in lung adenocarcinoma.</p>Purity:96.54% (SEC-HPLC) - 96.54% (SEC-HPLC)Color and Shape:Odour LiquidPROTAC EGFR degrader 3
CAS:<p>Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.</p>Formula:C60H77N13O5SColor and Shape:SolidMolecular weight:1092.4Insulin efsitora alfa
CAS:<p>Insulin efsitora alfa(LY-3209590) is an IR agonist and a fusion protein that binds a novel single-chain insulin variant to the structural domain of human IgG Fc</p>Purity:98.3% (SDS-PAGE); 98.1% (SEC-HPLC) - 98.3% (SDS-PAGE); 98.1% (SEC-HPLC)Color and Shape:LiquidEflapegrastim
CAS:<p>Eflapegrastim: humanized IgG4 antibody and G-CSF that boosts neutrophils and shortens neutropenia.</p>Color and Shape:LiquidBTK-IN-40
CAS:<p>BTK-IN-40 (compound 375) is an inhibitor of BTK.</p>Formula:C20H25N7O2Color and Shape:SolidMolecular weight:395.46YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Color and Shape:Odour LiquidEtevritamab
CAS:<p>Etevritamab is a monoclonal antibody that targets CD3E/EGFR.</p>Color and Shape:LiquidBTK inhibitor 17
CAS:<p>BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.</p>Formula:C25H24N6O3Purity:99.57% - 99.88%Color and Shape:SolidMolecular weight:456.5LDN-193189 2HCl
CAS:<p>LDN-193189 2HCl inhibits BMP signaling (ALK1/2/3/6), IC50: 0.8-16.7 nM; selective over TGF-β by 200-fold in C2C12 cells.</p>Formula:C25H24Cl2N6Purity:99.78%Color and Shape:SolidMolecular weight:479.4ODM-203 sodium
<p>ODM-203 sodium is an orally bioavailable selective and efficient FGFR and VEGFR inhibitor with antitumor activity, used in solid tumor research.</p>Formula:C26H20F2N5NaO2SPurity:99.89%Color and Shape:SolidMolecular weight:527.52[D-Ala2]-GIP (human)
CAS:<p>Potent GIP receptor agonist with 630 pM EC50; enhances cAMP, glucose control, insulin, cognition in diabetic/obese animals; neuroprotective in PD model.</p>Formula:C226H338N60O66SPurity:98%Color and Shape:SolidMolecular weight:4983.58Caffeic acid-pYEEIE
CAS:<p>Phosphopeptide ligand for the src SH2 domain (IC50 = 42 nM); displays 30-fold higher affinity than N-acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu (Ac-pYEEIE,).</p>Formula:C39H50N5O19PPurity:98%Color and Shape:SolidMolecular weight:923.82Ack1 inhibitor 2
CAS:<p>Ack1 Inhibitor 2, also referred to as Example 259, effectively inhibits Ack1 with an IC50 value of 0.46 μM [1].</p>Formula:C23H23N5O2Color and Shape:SolidMolecular weight:401.46AMX-818
<p>AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.</p>Color and Shape:Odour LiquidEP26
<p>EP26 is an orally active and potent inhibitor of EGFR and PD-L1, with IC50 values of 48.6 nM and 1.77 µM, respectively. It reduces the protein expression of p-EGFR and induces cell cycle arrest at the G0/G1 phase. EP26 shows potential for glioblastoma research.</p>Formula:C42H42ClFN4O5Molecular weight:736.28278MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Formula:C48H58ClFN8O12Color and Shape:SolidMolecular weight:993.47JAK 3 inhibitor IV
CAS:<p>JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to</p>Formula:C16H19NOPurity:98%Color and Shape:SolidMolecular weight:241.33SJF 1521
CAS:<p>SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.</p>Formula:C57H61ClFN7O9SPurity:99.20%Color and Shape:SolidMolecular weight:1074.65Fosgonimeton acetate
<p>Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).</p>Formula:C29H49N4O10PPurity:98.01%Color and Shape:SolidMolecular weight:644.69EGFR-IN-116
<p>EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.</p>Formula:C26H22N6O2SMolecular weight:482.1525PKA Inhibitor Fragment (6-22) amide TFA
<p>PKA Inhibitor Fragment (6-22) amide TFA (PKA Inhibitor Fragment (6-22) amide TFA) is an inhibitor of cAMP-dependent protein kinase A (PKA).</p>Formula:C82H131F3N28O26Purity:99.61% - 99.87%Color and Shape:SolidMolecular weight:1982.08SU 5616
CAS:<p>SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.</p>Formula:C13H8ClNOSPurity:98.84%Color and Shape:SoildMolecular weight:261.73EGFR-IN-127
<p>EGFR-IN-127 is an ATP-competitive inhibitor targeting EGFR, with IC50 values of 136.3 nM for EGFRdel19 and 161.2 nM for EGFRdel19/T790M/C797S. This compound holds potential for the study of non-small cell lung cancer (NSCLC).</p>Color and Shape:Odour SolidCalcineurin substrate
CAS:<p>Calcineurin Substrate is a Peptide from the regulatory RII subunit of cAMP-dependent protein kinase.</p>Formula:C92H150N28O29Purity:98%Color and Shape:SolidMolecular weight:2112.35Necitumumab
CAS:<p>Necitumumab (IMC-11F8) is a human monoclonal antibody against EGFR, an anti-angiogenic agent used in the treatment of advanced non-small cell lung cancer.</p>Purity:97.9% (SDS-PAGE); 99.1% (SEC-HPLC) - 97.9% (SDS-PAGE); 99.1% (SEC-HPLC)Color and Shape:LiquidMolecular weight:145.5 kDaEGFR-IN-124
<p>EGFR-IN-124 (compound 10A) is an EGFR inhibitor with an IC50 value of 0.54 μM, utilized in cancer research.</p>Color and Shape:Odour SolidMotesanib Diphosphate
CAS:<p>Motesanib Diphosphate (AMG 706) is the orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic</p>Formula:C22H23N5O·2H3PO4Purity:99.69%Color and Shape:SolidMolecular weight:569.44Leucettine L41
CAS:<p>Leucettine L41 (LeucettineL41) is an inhibitor of DYRKs/CLKs, preferentially targeting DYRK1A, and inhibits DYRK2.</p>Formula:C17H13N3O3Purity:99.08%Color and Shape:SolidMolecular weight:307.3Mecbotamab vedotin
CAS:<p>Mecbotamab vedotin (BA301) is an inhibitory IgG1 antibody that targets human tyrosine kinase receptor AXL and the humanized murine monoclonal BA301 γ1 chain. It can be utilized in the preparation of immunoconjugates for research into cancers expressing the Axl type.</p>Color and Shape:LiquidDSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Color and Shape:Odour SolidPROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Formula:C58H72ClFN12O8SColor and Shape:SolidMolecular weight:1151.78Cetuximab MMAE
<p>Cetuximab-MMAE, an antibody-drug conjugate (ADC), combines an EGFR-targeting antibody with Monomethyl auristatin E (MMAE) to investigate colorectal and head and neck cancers.</p>Color and Shape:LiquidMolecular weight:150 kDaKN1022
CAS:<p>KN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.</p>Formula:C21H22N6O5Purity:99.68%Color and Shape:SoildMolecular weight:438.44Laprituximab
CAS:<p>Laprituximab (J2898A) is a humanized anti-EGFR antibody used for synthesizing ADC compound Laprituximab emtansine.</p>Purity:>95%Color and Shape:LiquidAntiproliferative agent-57
<p>Antiproliferative agent-57 (compound M2) is a tumor angiogenesis inhibitor that suppresses VEGF secretion in SiHa cells under hypoxic conditions without inducing cytotoxicity (IC50=0.68 μM). It modulates the PI3K/AKT/mTOR and MAPK signaling pathways in tumor cells, thereby inhibiting the expression of HIF-1α and VEGF within tumor tissues.</p>Color and Shape:Odour SolidMS9449
CAS:<p>MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.</p>Formula:C60H76ClFN10O8SPurity:98%Color and Shape:SolidMolecular weight:1151.82EGFR-IN-43
<p>EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.</p>Formula:C50H55ClFN5O5Color and Shape:SolidMolecular weight:860.45EGFR-IN-15
CAS:<p>EGFR-IN-15 (compound I-005) is a potent EGFR inhibitor, exhibiting an IC50 value of 4 nM. This compound holds potential for oncological research applications.</p>Formula:C24H25BrN6O2Color and Shape:SolidMolecular weight:509.408(Pro3) GIP, human
CAS:<p>(Pro3) GIP, human: stable hGIPR full agonist, high affinity (Ki/Kd=0.90nM), for obesity-related diabetes research.</p>Formula:C226H338N60O64SColor and Shape:SolidMolecular weight:4951.53Istiratumab
CAS:<p>Istiratumab (M-6495) is a bispecific antibody against IGF-1R/ErbB3 for cancer research, promoting receptor degradation.</p>Color and Shape:LiquidPCI-33380
CAS:<p>PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.</p>Formula:C46H52BF2N11O3Purity:98%Color and Shape:SolidMolecular weight:855.8PD-149163 hydrochloride
<p>PD-149163 hydrochloride is a neurokinin B agonist with antipsychotic activity, used for research on neurological diseases.</p>Formula:C42H72ClN9O6Color and Shape:SolidMolecular weight:834.53Arginyl-Glutamine
CAS:<p>Arginyl-Glutamine (Arg-Gln) is a dipeptide nutritional supplement that protects neonatal mice from hyperoxia-induced lung injury, lowering VEGF levels.</p>Formula:C11H22N6O4Purity:95.2%Color and Shape:SolidMolecular weight:302.33
![[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP1259.webp&w=3840&q=75)
